Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression

Journal of Immunology

Volumn 189, Issue 9, 2012, Pages 4674-4683

  Corrales, Leticia ^a   Ajona, Daniel ^a   Rafail, Stavros ^b   Lasarte, Juan J ^a   Riezu Boj, Jose I ^a   Lambris, John D ^b   Rouzaut, Ana ^a,c   Pajares, Maria J ^a,d   Montuenga, Luis M ^a,d   Pio, Ruben ^a,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF NAVARRA   (Spain)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; INTERLEUKIN 6; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN ARG1; PROTEIN LAG3; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BRONCHUS MUCOSA; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CHEMOTAXIS; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; COMPLEMENT DEPOSITION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LEWIS CARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT;

ADENOCARCINOMA; ANIMALS; CARCINOMA, LEWIS LUNG; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; COMPLEMENT ACTIVATION; COMPLEMENT C5A; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNE TOLERANCE; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, ANAPHYLATOXIN C5A; RESPIRATORY MUCOSA; TUMOR MICROENVIRONMENT;

EID: 84867919350     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201654     Document Type: Article

References (67)

1. Walport, M. J. 2001. Complement. First of two parts. N. Engl. J. Med. 344: 1058-1066.
2. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797.
3. Klos, A., A. J. Tenner, K. O. Johswich, R. R. Ager, E. S. Reis, and J. Köhl. 2009. The role of the anaphylatoxins in health and disease. Mol. Immunol. 46: 2753-2766.
4. Bjørge, L., J. Hakulinen, O. K. Vintermyr, H. Jarva, T. S. Jensen, O. E. Iversen, and S. Meri. 2005. Ascitic complement system in ovarian cancer. Br. J. Cancer 92: 895-905. (Pubitemid 40462637)
5. Niculescu, F., H. G. Rus, M. Retegan, and R. Vlaicu. 1992. Persistent complement activation on tumor cells in breast cancer. Am. J. Pathol. 140: 1039-1043.
6. Niehans, G. A., D. L. Cherwitz, N. A. Staley, D. J. Knapp, and A. P. Dalmasso. 1996. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. Pathol. 149: 129-142. (Pubitemid 26230985)
7. Finch, A. M., A. K. Wong, N. J. Paczkowski, S. K. Wadi, D. J. Craik, D. P. Fairlie, and S. M. Taylor. 1999. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J. Med. Chem. 42: 1965-1974. (Pubitemid 29269629)
8. Yamakawa, M., K. Yamada, T. Tsuge, H. Ohrui, T. Ogata, M. Dobashi, and Y. Imai. 1994. Protection of thyroid cancer cells by complement-regulatory factors. Cancer 73: 2808-2817. (Pubitemid 24166270)
9. Jurianz, K., S. Ziegler, H. Garcia-Schüler, S. Kraus, O. Bohana-Kashtan, Z. Fishelson, and M. Kirschfink. 1999. Complement resistance of tumor cells: basal and induced mechanisms. Mol. Immunol. 36: 929-939. (Pubitemid 30100845)
10. Rutkowski, M. J., M. E. Sughrue, A. J. Kane, S. A. Mills, and A. T. Parsa. 2010. Cancer and the complement cascade. Mol. Cancer Res. 8: 1453-1465.
11. Markiewski, M. M., R. A. DeAngelis, F. Benencia, S. K. Ricklin-Lichtsteiner, A. Koutoulaki, C. Gerard, G. Coukos, and J. D. Lambris. 2008. Modulation of the antitumor immune response by complement. Nat. Immunol. 9: 1225-1235.
12. Nozaki, M., B. J. Raisler, E. Sakurai, J. V. Sarma, S. R. Barnum, J. D. Lambris, Y. Chen, K. Zhang, B. K. Ambati, J. Z. Baffi, and J. Ambati. 2006. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc. Natl. Acad. Sci. USA 103: 2328-2333. (Pubitemid 43271669)
13. Langer, H. F., K. J. Chung, V. V. Orlova, E. Y. Choi, S. Kaul, M. J. Kruhlak, M. Alatsatianos, R. A. Deangelis, P. A. Roche, P. Magotti, et al. 2010. Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood 116: 4395-4403.
14. Kohler, B. A., E. Ward, B. J. McCarthy, M. J. Schymura, L. A. Ries, C. Eheman, A. Jemal, R. N. Anderson, U. A. Ajani, and B. K. Edwards. 2011. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J. Natl. Cancer Inst. 103: 714-736.
15. Sautès-Fridman, C., J. Cherfils-Vicini, D. Damotte, S. Fisson, W. H. Fridman, I. Cremer, and M. C. Dieu-Nosjean. 2011. Tumor microenvironment is multifaceted. Cancer Metastasis Rev. 30: 13-25.
16. Nishioka, K., K. Kawamura, T. Hirayama, T. Kawashima, and K. Shimada. 1976. The complement system in tumor immunity: significance of elevated levels of complement in tumor bearing hosts. Ann. N. Y. Acad. Sci. 276: 303-315.
17. Varsano, S., L. Rashkovsky, H. Shapiro, D. Ophir, and T. Mark-Bentankur. 1998. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism (s) of resistance. Clin. Exp. Immunol. 113: 173-182. (Pubitemid 28352834)
18. Ajona, D., Z. Castaño, M. Garayoa, E. Zudaire, M. J. Pajares, A. Martinez, F. Cuttitta, L. M. Montuenga, and R. Pio. 2004. Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res. 64: 6310-6318. (Pubitemid 39129436)
19. Ajona, D., Y. F. Hsu, L. Corrales, L. M. Montuenga, and R. Pio. 2007. Downregulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J. Immunol. 178: 5991-5998. (Pubitemid 46674397)
20. Okroj, M., Y. F. Hsu, D. Ajona, R. Pio, and A. M. Blom. 2008. Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol. Immunol. 45: 169-179. (Pubitemid 47331646)
21. Ramirez, R. D., S. Sheridan, L. Girard, M. Sato, Y. Kim, J. Pollack, M. Peyton, Y. Zou, J. M. Kurie, J. M. Dimaio, et al. 2004. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res. 64: 9027-9034. (Pubitemid 39665513)
22. Sato, M., M. B. Vaughan, L. Girard, M. Peyton, W. Lee, D. S. Shames, R. D. Ramirez, N. Sunaga, A. F. Gazdar, J. W. Shay, and J. D. Minna. 2006. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res. 66: 2116-2128.
23. Travis, W. D., E. Brambilla, H. K. Müller-Hermelink, and C. C. Harris. 2004. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, France.
24. Qu, H., D. Ricklin, H. Bai, H. Chen, E. S. Reis, M. Maciejewski, A. Tzekou, R. A. Deangelis, R. R. Resuello, F. Lupu, et al. 2012. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology. In press.
25. Nguewa, P. A., J. Agorreta, D. Blanco, M. D. Lozano, J. Gomez-Roman, B. A. Sanchez, I. Valles, M. J. Pajares, R. Pio, M. J. Rodriguez, et al. 2008. Identification of importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens. BMC Mol. Biol. 9: 103.
26. Ponce, M. L. 2001. Methods in Molecular Medicine. Humana Press, Totowa, NJ.
27. Kubota, Y., H. K. Kleinman, G. R. Martin, and T. J. Lawley. 1988. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J. Cell Biol. 107: 1589-1598.
28. Larrea, E., R. Aldabe, E. Molano, C. M. Fernandez-Rodriguez, A. Ametzazurra, M. P. Civeira, and J. Prieto. 2006. Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: in vivo and in vitro studies. Gut 55: 1188-1196. (Pubitemid 44085689)
29. Strainic, M. G., J. Liu, D. Huang, F. An, P. N. Lalli, N. Muqim, V. S. Shapiro, G. R. Dubyak, P. S. Heeger, and M. E. Medof. 2008. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28: 425-435.
30. Tu, Z., H. Bu, J. E. Dennis, and F. Lin. 2010. Efficient osteoclast differentiation requires local complement activation. Blood 116: 4456-4463.
31. Ricklin, D., and J. D. Lambris. 2008. Compstatin: a complement inhibitor on its way to clinical application. Adv. Exp. Med. Biol. 632: 273-292.
32. Huber-Lang, M., J. V. Sarma, F. S. Zetoune, D. Rittirsch, T. A. Neff, S. R. McGuire, J. D. Lambris, R. L. Warner, M. A. Flierl, L. M. Hoesel, et al. 2006. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12: 682-687. (Pubitemid 43865238)
33. Selander, B., U. Mårtensson, A. Weintraub, E. Holmström, M. Matsushita, S. Thiel, J. C. Jensenius, L. Truedsson, and A. G. Sjöholm. 2006. Mannanbinding lectin activates C3 and the alternative complement pathway without involvement of C2. J. Clin. Invest. 116: 1425-1434.
34. Zhang, M., K. Takahashi, E. M. Alicot, T. Vorup-Jensen, B. Kessler, S. Thiel, J. C. Jensenius, R. A. Ezekowitz, F. D. Moore, and M. C. Carroll. 2006. Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury. J. Immunol. 177: 4727-4734. (Pubitemid 44469806)
35. Amara, U., D. Rittirsch, M. Flierl, U. Bruckner, A. Klos, F. Gebhard, J. D. Lambris, and M. Huber-Lang. 2008. Interaction between the coagulation and complement system. Adv. Exp. Med. Biol. 632: 71-79.
36. Markiewski, M. M., B. Nilsson, K. N. Ekdahl, T. E. Mollnes, and J. D. Lambris. 2007. Complement and coagulation: strangers or partners in crime? Trends Immunol. 28: 184-192. (Pubitemid 46476881)
37. Huber-Lang, M., E. M. Younkin, J. V. Sarma, N. Riedemann, S. R. McGuire, K. T. Lu, R. Kunkel, J. G. Younger, F. S. Zetoune, and P. A. Ward. 2002. Generation of C5a by phagocytic cells. Am. J. Pathol. 161: 1849-1859. (Pubitemid 35265542)
38. Wong, R. F., T. L. Chang, and R. D. Feinman. 1982. Reaction of antithrombin with proteases. Nature of the reaction with trypsin. Biochemistry 21: 6-12.
39. Wetsel, R. A., and W. P. Kolb. 1983. Expression of C5a-like biological activities by the fifth component of human complement (C5) upon limited digestion with noncomplement enzymes without release of polypeptide fragments. J. Exp. Med. 157: 2029-2048. (Pubitemid 13060901)
40. Rawlings, N. D., F. R. Morton, C. Y. Kok, J. Kong, and A. J. Barrett. 2008. MEROPS: the peptidase database. Nucleic Acids Res. 36(Database issue): D320-D325. (Pubitemid 351149743)
41. Miyata, S., N. Koshikawa, S. Higashi, Y. Miyagi, Y. Nagashima, S. Yanoma, Y. Kato, H. Yasumitsu, and K. Miyazaki. 1999. Expression of trypsin in human cancer cell lines and cancer tissues and its tight binding to soluble form of Alzheimer amyloid precursor protein in culture. J. Biochem. 125: 1067-1076. (Pubitemid 29332988)
42. Cox, G., W. P. Steward, and K. J. O'Byrne. 1999. The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax 54: 169-179. (Pubitemid 29101363)
43. Henneke, I., S. Greschus, R. Savai, M. Korfei, P. Markart, P. Mahavadi, R. T. Schermuly, M. Wygrecka, J. Stürzebecher, W. Seeger, et al. 2010. Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model. Am. J. Respir. Crit. Care Med. 181: 611-619.
44. Motz, G. T., and G. Coukos. 2011. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 11: 702-711.
45. Jagels, M. A., P. J. Daffern, and T. E. Hugli. 2000. C3a and C5a enhance granulocyte adhesion to endothelial and epithelial cell monolayers: epithelial and endothelial priming is required for C3a-induced eosinophil adhesion. Immunopharmacology 46: 209-222. (Pubitemid 30085542)
46. Albrecht, E. A., A. M. Chinnaiyan, S. Varambally, C. Kumar-Sinha, T. R. Barrette, J. V. Sarma, and P. A. Ward. 2004. C5a-induced gene expression in human umbilical vein endothelial cells. Am. J. Pathol. 164: 849-859. (Pubitemid 38235467)
47. Langeggen, H., E. Johnson, and G. Hetland. 2001. Effects of C5a and FMLP on interleukin-8 production and proliferation of human umbilical vein endothelial cells. Inflammation 25: 83-89. (Pubitemid 32295743)
48. Kurihara, R., K. Yamaoka, N. Sawamukai, S. Shimajiri, K. Oshita, S. Yukawa, M. Tokunaga, S. Iwata, K. Saito, K. Chiba, and Y. Tanaka. 2010. C5a promotes migration, proliferation, and vessel formation in endothelial cells. Inflamm. Res. 59: 659-666.
49. Schraufstatter, I. U., K. Trieu, L. Sikora, P. Sriramarao, and R. DiScipio. 2002. Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J. Immunol. 169: 2102-2110. (Pubitemid 34857676)
50. Cross, M. J., and L. Claesson-Welsh. 2001. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 22: 201-207. (Pubitemid 32244307)
51. Ostrand-Rosenberg, S., and P. Sinha. 2009. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182: 4499-4506.
52. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
53. Cao, X. 2010. Regulatory T cells and immune tolerance to tumors. Immunol. Res. 46: 79-93.
54. Montuenga, L. M., and R. Pio. 2007. Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10. Eur. Respir. J. 30: 608-610. (Pubitemid 351194816)
55. De Vita, F., M. Orditura, G. Galizia, C. Romano, A. Roscigno, E. Lieto, and G. Catalano. 2000. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 117: 365-373. (Pubitemid 30111584)
56. Brichory, F. M., D. E. Misek, A. M. Yim, M. C. Krause, T. J. Giordano, D. G. Beer, and S. M. Hanash. 2001. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc. Natl. Acad. Sci. USA 98: 9824-9829. (Pubitemid 32769388)
57. Pine, S. R., L. E. Mechanic, L. Enewold, A. K. Chaturvedi, H. A. Katki, Y. L. Zheng, E. D. Bowman, E. A. Engels, N. E. Caporaso, and C. C. Harris. 2011. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J. Natl. Cancer Inst. 103: 1112-1122.
58. Rodriguez, P. C., D. G. Quiceno, J. Zabaleta, B. Ortiz, A. H. Zea, M. B. Piazuelo, A. Delgado, P. Correa, J. Brayer, E. M. Sotomayor, et al. 2004. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits Tcell receptor expression and antigen-specific T-cell responses. Cancer Res. 64: 5839-5849. (Pubitemid 39095585)
59. Hagenbaugh, A., S. Sharma, S. M. Dubinett, S. H.Wei, R. Aranda, H. Cheroutre, D. J. Fowell, S. Binder, B. Tsao, R. M. Locksley, et al. 1997. Altered immune responses in interleukin 10 transgenic mice. J. Exp. Med. 185: 2101-2110. (Pubitemid 27265994)
60. Kryczek, I., L. Zou, P. Rodriguez, G. Zhu, S. Wei, P. Mottram, M. Brumlik, P. Cheng, T. Curiel, L. Myers, et al. 2006. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203: 871-881.
61. Scalapino, K. J., and D. I. Daikh. 2008. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol. Rev. 223: 143-155. (Pubitemid 351986184)
62. Read, S., V. Malmström, and F. Powrie. 2000. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exp. Med. 192: 295-302. (Pubitemid 30470312)
63. Huang, C. T., C. J. Workman, D. Flies, X. Pan, A. L. Marson, G. Zhou, E. L. Hipkiss, S. Ravi, J. Kowalski, H. I. Levitsky, et al. 2004. Role of LAG-3 in regulatory T cells. Immunity 21: 503-513. (Pubitemid 39370506)
64. Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, et al. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8: 793-800.
65. Konishi, J., K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita, and M. Nishimura. 2004. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin. Cancer Res. 10: 5094-5100. (Pubitemid 39106851)
66. Brahmer, J. R., S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366: 2455-2465.
67. Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366: 2443-2454.